Physician profile
Frederick E Kuhn
NPI 1245233535
$5,101.20
in general payments reported to CMS, 2019-2025
28 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $61.50 · 2021: $310 · 2022: $474 · 2023: $1,015 · 2024: $1,326 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Consulting Fee: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.87 |
| Consulting Fee | $370.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $858.48 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $645.62 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $629.94 | 2019-2025 | |
| Abbott Laboratories | $462.62 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Quartet |
| Scpharmaceuticals INC. | $338.43 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.58 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $208.93 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $204.44 | 2019-2023 | Watchman |
| Baxter Healthcare | $194.79 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $181.04 | 2019-2024 | Xarelto |
| Amgen INC. | $156.40 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $122.61 | 2019-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $121.94 | 2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $114.80 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.32 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $74.88 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Novo Nordisk INC | $71.64 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $63.94 | 2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $60.01 | 2019-2023 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $50.34 | 2019 | |
| Gilead Sciences, INC. | $37.85 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.46 | 2019-2020 | |
| Atricure, INC. | $24.57 | 2023 | |
| Pfizer INC. | $23.88 | 2019 | |
| Irhythm Technologies, INC. | $20.31 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $18.97 | 2019 | |
| Heartflow, INC. | $16.39 | 2025 | |
| Astellas Pharma US INC | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.